

Appointment of Chief Financial Officer

MINNEAPOLIS, United States and BRISBANE, Australia 7 September 2026: Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, advises that on 4 September 2026 US Eastern Time (5 September 2026 AEST) Brent Moen was appointed as its Chief Financial Officer, effective September 11, 2026 US Eastern Time (12 September 2026 AEST).

Mr. Moen is an experienced financial executive with more than 25 years of leadership experience, including Chief Financial Officer roles at both public and private companies. He has extensive expertise in capital markets, investor relations, mergers and acquisitions, and scaling growth-oriented organizations, including medical technology companies. Mr. Moen previously served as Chief Financial Officer of LifeLens Technologies from September 2023 to March 2026, Chief Financial Officer of Tactile Systems Technology from September 2018 to April 2023, and Chief Financial Officer of Entellus Medical from May 2016 to March 2018. Mr. Moen holds a Bachelor of Accountancy from the University of North Dakota.

Transition of Matthew McDonnell

Effective as of September 11, 2026, Matthew McDonnell will commence service as the Company's Head of Australia and will cease to serve as Chief Financial Officer of the Company.

ENDS

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.

Anteris' lead product, the DurAVR® Transcatheter Heart Valve ("THV"), was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris' patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.



Authorisation and Additional information

This announcement was authorised for release on the ASX by the Vice Chairman and Chief Executive Officer.

For more information:

Global Investor Relations

investors@anteristech.com

Debbie Ormsby

Anteris Technologies Global Corp.

+61 1300 550 310 | +61 7 3152 3200

Investor Relations (US)

mchatterjee@bplifescience.com

Malini Chatterjee, Ph.D.

Blueprint Life Science Group

+1 917 330 4269

Website

www.anteristech.com

X

@AnterisTech

LinkedIn

<https://www.linkedin.com/company/anteristech>

